



TESARO, Inc.  
Investor Relations Department  
1000 Winter St., Ste. 3300  
Waltham, MA 02451  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#) 

#### NASDAQ: TSRO

Last Trade: 118.86

Trade Time: 4:00 PM ET  
8/21/2017

Change: 5.00   
(+4.391%)

Day Range 113.12 - 119.46

52-Week Range 83.26 - 192.94


Volume 1,393,334

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Founded in 2010, TESARO is a publicly-traded oncology focused company dedicated to improving the lives of cancer patients. The Company intends to leverage the experience and competencies of its management team to identify, acquire and develop promising drug candidates. Upon successful development and regulatory approval of any of our product candidates, TESARO intends to make them available to cancer patients in North America, Europe and China through its own commercialization efforts and to establish a network of licensees and distributors in other geographic areas. For more information... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

8/08/2017

[TESARO Announces Second-Quarter 2017 Operating Results](#)

7/27/2017

[TESARO and Takeda Enter Into Exclusive Licensing Agreement to Develop and Commercialize Novel Cancer Therapy Niraparib in Japan](#)

7/25/2017

[TESARO to Announce Second-Quarter 2017 Financial Results on August 8, 2017](#)

6/29/2017

[TESARO Joins OCRFA as Presenting Sponsor of the 2017 Ovarian Cancer National Conference](#)

6/28/2017

[TESARO Announces Lonnie Moulder and Mary Lynne Hedley Named EY Entrepreneurs of the Year® New England](#)

## Financials [\[ View all \]](#)

2/28/2017

[Annual Report \(10-K\)](#)

4/07/2017

[Proxy Statement \(DEF 14A\)](#)

8/08/2017

[Quarterly Report \(10-Q\)](#)

5/09/2017

[Quarterly Report \(10-Q\)](#)

11/04/2016

[Quarterly Report \(10-Q\)](#)